283例鼻咽癌超分割放疗的近远期临床疗效分析  

Short and long term clinical outcome of 283 cases of nasopharyngeal carcinoma patients treated with hyperfractionated radiotherapy

作　　者：徐志渊[1] 林连兴[1] 张晓平[1] 李忆璇[1] 

机构地区：[1]汕头市中心医院放疗科,515031

出　　处：《国际肿瘤学杂志》2008年第9期711-713,共3页Journal of International Oncology

摘　　要：目的探讨超分割放疗治疗鼻咽癌的疗效和并发症情况。方法对283例鼻咽癌患者采用超分割放疗治疗，部分病例加用5-氟尿嘧啶加顺铂或卡铂方案化疗，放疗采用60^Co-γ线外照射，每次1．2Gy，每天2次，每周5d，间隔≥6h，全疗程鼻咽中位放疗剂量72Gy，颈部中位放疗剂量68．4Gy。结果放疗过程中黏膜反应≥3级的病例占12．4％，放化疗结束时完全缓解率为93．6％，1年生存率为93．6％，2年生存率82．7％，5年生存率为60．1％。结论超分割放疗患者能耐受，疗效好，为鼻咽癌患者提供了一种可能有效的治疗选择，其确切疗效有待大规模临床试验验证。Objective To approach the therapeutic effects and complication of hyperfractionated radiotherapy for nasopharyngeal carcinoma. Methods From January 2000 to November 2002,283 patients with nasopharyngeal carcinoma were treated with hyperfractionated radiotherapy. For hyperfractionated radiotherapy, γ-ray from 60^Co was performed and two fractions of 1.2 Gy were given daily,with an interval of t≥6 h,5 days per week to a median dose of 72 Gy for nasopharynx and 68.4 Gy for neck. For some patients, carboplatin or cisplatin and 5-fluorouracil were transfused. Results The incidence rate of 1〉3 grade acute mucositis was 12. 4%. The complete remission rate after treatment was 93.6%. The 1,2 and 5 year survival rate was 93.6% ,82. 7% and 60. 1% respectively. Conclusion patients treated with hyperfractionated radiotherapy have good tolerance and therapeutic effect. It provids a treatment means for nasopharyngeal carcinoma. But it must be validated by the large-scale clinical trials.

关 键 词：鼻咽肿瘤 放射疗法 辐射损伤 预后 

分 类 号：R739.63[医药卫生—肿瘤]